The SOS Trial: Safety of Simvastatin in Patients with Pulmonary Lymphangioleiomyomatosis and with Tuberous Sclerosis Complex

Brief Description Of Study

This 4-month trial is a pilot safety study of simvastatin in patients with sporadic pulmonary LAM or LAM associated with Tuberous Sclerosis.

Clinical Study Identifier: TX1012

Detailed Study Description

The objective of the trial is to determine the safety of simvastatin in combination with either sirolimus or everolimus in patients with LAM. To qualify for the trial, women with LAM must be 18 years of age or older, be able to give informed consent and have abnormal lung function (specifically, a postbronchodilator, forced expiratory volume in one second (FEV1) of 70% of predicted or less). The SOS Trial will require six visits over 5 months during which pulmonary function studies, blood tests, questionnaires and x-rays are administered.

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: The SOS Trial: Safety of Simvastatin in Patients with Pulmonary Lymphangioleiomyomatosis and with Tuberous Sclerosis Complex
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.